NCT00326183View on ClinicalTrials.gov

Hepatitis A Vaccine, Inactivated and Measles, Mumps, Rubella and Varicella Virus Vaccine Live Safety Study (V251-066)(COMPLETED)

PHASE4CompletedINTERVENTIONAL
Enrollment

1,800

Participants

Timeline

Start Date

March 26, 2007

Primary Completion Date

January 15, 2008

Study Completion Date

January 15, 2008

Conditions
Hepatitis AMeaslesMumpsRubellaChickenpox
Interventions
BIOLOGICAL

VAQTA®

0.5 ml injection VAQTA®; 2nd 0.5 ml injection VAQTA® 24 week period of treatment.

BIOLOGICAL

ProQuad

0.5 ml injection ProQuad; 2nd 0.5 ml injection ProQuad®. 24 week period of treatment.

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT00326183 - Hepatitis A Vaccine, Inactivated and Measles, Mumps, Rubella and Varicella Virus Vaccine Live Safety Study (V251-066)(COMPLETED) | Biotech Hunter | Biotech Hunter